Aclara and GSK agreement
Aclara BioSciences from Mountain View, CA, US, has entered into an eTag access agreement with GlaxoSmithKline (GSK), under which GSK will gain access to Aclara's proprietary eTag assay system for use in its biopharmaceutical research and development activities.
Aclara BioSciences from Mountain View, CA, US, has entered into an eTag access agreement with GlaxoSmithKline (GSK), under which GSK will gain access to Aclara's proprietary eTag assay system for use in its biopharmaceutical research and development activities.
In addition to leveraging Aclara's state of the art custom assay development services GSK will also utilise eTag assay reagent products and software for multiplexed gene expression profiling studies.
'We are very pleased that GSK has chosen to in-corporate Aclara's eTag assay system into its drug discovery and development programs,' said Thomas Klopack, Aclara's ceo. 'This agreement will enable GSK to use the eTag assay system to gain significant insight into biology in a high throughput, targeted fashion, thereby accelerating the advancement of new biopharmaceuticals.'
About the eTag Assay System
The eTag Assay System is a high performance, high throughput system for the study of 10s to 100s of genes, proteins, and cell-based antigens across thousands of samples. The eTag platform makes it possible for researchers to measure multiple aspects of a complex biological system, enabling the concurrent study of gene expression, protein expression, cell signaling and pathway activation, protein-protein interaction, and cell receptor binding - all in the same sample and with the same platform. The system uses Aclara's proprietary eTag reporters to multiplex the analysis of genes and/or proteins. Specific molecular binding events result in the release of electrophoretically distinct eTag reporters, which are then resolved by standard capillary electrophoresis to provide precise, sensitive quantitation of multiple analytes - directly from cell lysates.